Author: Tongrui Biomedicine (Shanghai) Co., LTD

Posted Date:

April 28, 2026

C-Ray Therapeutics Receives FDA Acceptance of Type II Drug Master File for Copper-64 (Cu-64)

Tongrui Biomedicine (Shanghai) Co., LTD

April 28, 2026
C-Ray Therapeutics and SHINE Technologies Enter Strategic Partnership for Exclusive Distribution of No-Carrier-Added Lu-177 in Mainland China

Tongrui Biomedicine (Shanghai) Co., LTD

March 26, 2026
C-Ray Therapeutics Achieves AAALAC International Full Accreditation, Reinforcing Commitment to Excellence in Preclinical Research

Tongrui Biomedicine (Shanghai) Co., LTD

February 24, 2026